Adeona taps James Kuo as CEO, chairman and president

> Adeona Pharmaceuticals has appointed James Kuo as chairman, CEO and president. Release

> Neuraltus Pharmaceuticals has announced that Andrew Gengos has been named as president and CEO. Release

> Xencor has tapped Edgardo Baracchini as chief business officer. He brings more than 15 years of transactional experience to the company. Release

> Aton Pharma has tapped Michael Richardson as VP, commercial operations for the newly formed orphan drug business unit. Donald Fishbein assumes the same role for the ophthalmic business unit. Release

> BioSante Pharmaceuticals has appointed Jeffrey Winkelman as VP, oncology programs. Release

> SuppreMol has reported that Robert Phelps has joined the company as head of business development & licensing. Release

> Biogen Idec has announced that John Richert will be joining the company as a senior fellow in neurology R&D, and Nancy Richert will be joining as a fellow in neurology R&D. Release

> Trevena has named David Soergel as VP and head of clinical development. In this role, Soergel is responsible for shaping Trevena's clinical strategy and the operational execution of its development programs. Release

> Stem Cell Therapy International has announced that Dr. Hoon Han has been elected chairman of the company's board of directors effective immediately. Release

> Neurocrine Biosciences announced that it has appointed William Rastetter to its board of directors effective immediately. Release

> Immunomedics has named Kenneth Zuerblis to the company's board of directors. Release

 > Bionovo has appointed quality control and botanical authentication expert Paul Pui-Hay But to the company's scientific advisory board. Release

> Amicus Therapeutics board of directors names CEO John Crowley chairman and Donald Hayden, Jr. lead independent director. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.